Clinical Trials Directory

Trials / Terminated

TerminatedNCT02105623

EARly Prevention of aTHeroma Progression

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
111 (actual)
Sponsor
CHEOL WHAN LEE, M.D., Ph.D · Academic / Other
Sex
All
Age
35 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare standard therapy (risk factor control, life style modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on progression of coronary atherosclerosis in statin naive individuals who have mild CAD (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein) cholesterol levels(\<130mg/dl).

Conditions

Interventions

TypeNameDescription
BEHAVIORALStandard TherapyRisk factor control Diet Exercise for 24months
DRUGRosuvastatinRisk factor control rosuvastatin 5mg/day for 24months

Timeline

Start date
2014-06-01
Primary completion
2018-03-01
Completion
2018-03-01
First posted
2014-04-07
Last updated
2018-06-25

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02105623. Inclusion in this directory is not an endorsement.